» Articles » PMID: 8864423

Effects of Bile Salt Hydrophobicity on Crystallization of Cholesterol in Model Bile

Overview
Publisher Wiley
Specialty General Medicine
Date 1996 Jul 1
PMID 8864423
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Precipitation of cholesterol crystals is an essential step in gallstone formation. In the present study we found much faster and more extensive precipitation of various cholesterol crystal shapes in whole model biles containing the hydrophobic bile salt taurodeoxycholate than in biles containing the relatively hydrophilic taurocholate. Addition of taurodeoxycholate to isolated cholesterol-phospholipid vesicles also induced more crystallization than taurocholate. Crystallization behaviour in whole model biles and in vesicles after addition of corresponding bile salts was very similar. The very hydrophilic bile salts tauroursodeoxycholate and taurohyodeoxycholate never induced crystallization from vesicles, and crystallization in corresponding whole model biles did not occur. These bile salts also reduced crystallization dose dependently after addition of taurodeoxycholate to vesicles. Ultracentrifugation experiments suggested a higher vesicular cholesterol-phospholipid bile salts. These findings indicate that bile salt hydrophobicity influences shape of cholesterol crystals and extent of crystallization, possibly by modulating the vesicular cholesterol-phospholipid ratio.

Citing Articles

Gastrointestinal defects in gallstone and cholecystectomized patients.

Di Ciaula A, Molina-Molina E, Bonfrate L, Wang D, Dumitrascu D, Portincasa P Eur J Clin Invest. 2018; 49(3):e13066.

PMID: 30592298 PMC: 8118136. DOI: 10.1111/eci.13066.


Recent advances in understanding and managing cholesterol gallstones.

Di Ciaula A, Portincasa P F1000Res. 2018; 7.

PMID: 30345010 PMC: 6173119. DOI: 10.12688/f1000research.15505.1.


An update on the pathogenesis of cholesterol gallstone disease.

Di Ciaula A, Wang D, Portincasa P Curr Opin Gastroenterol. 2017; 34(2):71-80.

PMID: 29283909 PMC: 8118137. DOI: 10.1097/MOG.0000000000000423.


Therapy of gallstone disease: What it was, what it is, what it will be.

Portincasa P, Di Ciaula A, Bonfrate L, Wang D World J Gastrointest Pharmacol Ther. 2012; 3(2):7-20.

PMID: 22577615 PMC: 3348960. DOI: 10.4292/wjgpt.v3.i2.7.


Targets for current pharmacologic therapy in cholesterol gallstone disease.

Di Ciaula A, Wang D, Wang H, Bonfrate L, Portincasa P Gastroenterol Clin North Am. 2010; 39(2):245-64, viii-ix.

PMID: 20478485 PMC: 2915454. DOI: 10.1016/j.gtc.2010.02.005.